These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 35278845)
1. Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system. Perdrizet K; Stockley TL; Law JH; Smith A; Zhang T; Fernandes R; Shabir M; Sabatini P; Youssef NA; Ishu C; Li JJ; Tsao MS; Pal P; Cabanero M; Schwock J; Ko HM; Boerner S; Ruff H; Shepherd FA; Bradbury PA; Liu G; Sacher AG; Leighl NB Cancer Treat Res Commun; 2022; 31():100534. PubMed ID: 35278845 [TBL] [Abstract][Full Text] [Related]
2. The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer. Nesline MK; Subbiah V; Previs RA; Strickland KC; Ko H; DePietro P; Biorn MD; Cooper M; Wu N; Conroy J; Pabla S; Zhang S; Wallen ZD; Sathyan P; Saini K; Eisenberg M; Caveney B; Severson EA; Ramkissoon S Oncol Ther; 2024 Jun; 12(2):329-343. PubMed ID: 38502426 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569 [TBL] [Abstract][Full Text] [Related]
4. Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing. Suh JH; Schrock AB; Johnson A; Lipson D; Gay LM; Ramkissoon S; Vergilio JA; Elvin JA; Shakir A; Ruehlman P; Reckamp KL; Ou SI; Ross JS; Stephens PJ; Miller VA; Ali SM Oncologist; 2018 Jul; 23(7):776-781. PubMed ID: 29540602 [TBL] [Abstract][Full Text] [Related]
5. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative. Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220 [TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Comprehensive Genomic Profiling in Patients With Non-Small Cell Lung Cancer for the Colombian Health System. Gamboa O; Bonilla CE; Quitian D; Torres GF; Buitrago G; Cardona AF Value Health Reg Issues; 2024 Jan; 39():115-125. PubMed ID: 38101152 [TBL] [Abstract][Full Text] [Related]
7. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042 [TBL] [Abstract][Full Text] [Related]
8. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer. Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885 [TBL] [Abstract][Full Text] [Related]
9. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532 [TBL] [Abstract][Full Text] [Related]
10. ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissue. Mersiades AJ; Solomon BJ; Thomas DM; Lee CK; Cummins MM; Sebastian L; Ballinger ML; Collignon E; Turnbull OM; Yip S; Morton RL; Brown C; Wheeler PJ; Itchins M; Simes RJ; Pavlakis N Future Oncol; 2024 Mar; 20(7):361-371. PubMed ID: 37767626 [TBL] [Abstract][Full Text] [Related]
11. How clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer? A systematic review. Torres GF; Bonilla CE; Buitrago G; Arrieta O; Malapelle U; Rolfo C; Cardona AF Crit Rev Oncol Hematol; 2021 Oct; 166():103459. PubMed ID: 34461270 [TBL] [Abstract][Full Text] [Related]
12. Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients. Patel YP; Husereau D; Leighl NB; Melosky B; Nam J Curr Oncol; 2021 Dec; 28(6):5278-5294. PubMed ID: 34940080 [TBL] [Abstract][Full Text] [Related]
13. Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry. Huang RSP; Severson E; Haberberger J; Duncan DL; Hemmerich A; Edgerly C; Ferguson NL; Frampton G; Owens C; Williams E; Elvin J; Vergilio JA; Killian JK; Lin D; Morley S; McEwan D; Holmes O; Danziger N; Cohen MB; Sathyan P; McGregor K; Reddy P; Venstrom J; Anhorn R; Alexander B; Brown C; Ross JS; Ramkissoon SH Pathol Oncol Res; 2021; 27():592997. PubMed ID: 34257540 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive genomic profiling for non-small-cell lung cancer: health and budget impact. Johnston KM; Sheffield BS; Yip S; Lakzadeh P; Qian C; Nam J Curr Oncol; 2020 Dec; 27(6):e569-e577. PubMed ID: 33380872 [TBL] [Abstract][Full Text] [Related]
15. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761 [TBL] [Abstract][Full Text] [Related]
16. Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan. Tang W; Hanada K; Motoo Y; Sakamaki H; Oda T; Furuta K; Abutani H; Ito S; Tsutani K J Med Econ; 2023; 26(1):614-626. PubMed ID: 37073487 [TBL] [Abstract][Full Text] [Related]
17. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency. Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052 [TBL] [Abstract][Full Text] [Related]
18. Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study. Normanno N; De Luca A; Abate RE; Morabito A; Milella M; Tabbò F; Curigliano G; Masini C; Marchetti P; Pruneri G; Guarneri V; Frassineti GL; Fasola G; Adamo V; Daniele B; Berardi R; Feroce F; Maiello E; Pinto C Eur J Cancer; 2023 Jul; 187():174-184. PubMed ID: 37167765 [TBL] [Abstract][Full Text] [Related]
19. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908 [TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling. Madison R; Schrock AB; Castellanos E; Gregg JP; Snider J; Ali SM; Miller VA; Singal G; Alexander BM; Venstrom JM; Chung JH Lung Cancer; 2020 Oct; 148():69-78. PubMed ID: 32823229 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]